(Q34542391)

2 August 2017

1 reference

title

H1-Antihistamines: more relevant than ever in the treatment of allergic disorders (English)

1 reference

2 August 2017

1 reference

1

F Estelle R Simons

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

The Journal of Allergy and Clinical Immunology

2 August 2017

published in

1 reference

2 August 2017

volume

112

1 reference

2 August 2017

issue

4 Suppl

1 reference

2 August 2017

page(s)

S42-52

1 reference

The pharmacology and use of H1-receptor-antagonist drugs

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Specific C-receptors for itch in human skin.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Clinical pharmacology of new histamine H1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Pharmacokinetics and pharmacodynamics of ebastine in children

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Skin concentrations of H1-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Desloratadine: A new, nonsedating, oral antihistamine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Effects of antihistamines in adult asthma: a meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Allergic rhinobronchitis: the asthma-allergic rhinitis link

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

1 reference

7 January 2021

Prevention of acute urticaria in young children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Non-cardiac adverse effects of antihistamines (H1-receptor antagonists).

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Occupational injuries and medication use.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Loss of work productivity due to illness and medical treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Comparison of the central nervous system effects produced by six H1-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Mechanism of the cardiotoxic actions of terfenadine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2803%2901876-1

7 January 2021

10.1016/S0091-6749(03)01876-1

Identifiers

DOI

1 reference

2 August 2017

1 reference